Anavex Life Sciences (AVXL) to Release Quarterly Earnings on Tuesday

Anavex Life Sciences (NASDAQ:AVXL) is projected to issue its Q4 2025 results before the market opens on Tuesday, November 25th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Friday, December 12, 2025 at 12:30 PM ET.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock traded up $0.04 on Wednesday, hitting $3.54. 617,960 shares of the company traded hands, compared to its average volume of 1,323,639. Anavex Life Sciences has a 52 week low of $2.86 and a 52 week high of $14.44. The business has a 50-day simple moving average of $8.25 and a 200 day simple moving average of $9.09. The stock has a market capitalization of $303.96 million, a P/E ratio of -6.18 and a beta of 0.92.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP increased its position in shares of Anavex Life Sciences by 6.5% during the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock valued at $9,229,000 after purchasing an additional 63,685 shares during the last quarter. Invesco Ltd. lifted its position in Anavex Life Sciences by 55.8% in the second quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock worth $7,966,000 after buying an additional 309,605 shares during the last quarter. UBS Group AG boosted its stake in Anavex Life Sciences by 3.8% during the third quarter. UBS Group AG now owns 491,977 shares of the biotechnology company’s stock worth $4,379,000 after buying an additional 17,823 shares during the period. Private Advisor Group LLC boosted its stake in Anavex Life Sciences by 14.0% during the third quarter. Private Advisor Group LLC now owns 455,125 shares of the biotechnology company’s stock worth $4,051,000 after buying an additional 55,900 shares during the period. Finally, Bank of America Corp DE increased its position in Anavex Life Sciences by 3.7% during the third quarter. Bank of America Corp DE now owns 170,886 shares of the biotechnology company’s stock valued at $1,521,000 after acquiring an additional 6,157 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on AVXL shares. Wall Street Zen cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 23rd. Jones Trading cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, October 7th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $44.00.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.